CLL and Combination Therapy

A phase II study was undertaken to examine the effectiveness of rituximab and lenalidomide in patients with chronic lymphocytic leukaemia (CLL) who had not been treated (treatment naïve).

Patients were randomised based on their age: in Arm A the median age was 57 years and in Arm B it was 70 years. The response rate in Arm A was 95% with 20% of patients achieving a complete response (CR). In Arm B, 79% of patients achieved a response and 11% were CRs. Median progression-free survival was 19 months for Arm A and 20 months for Arm B. For more information, click here.


Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe


Have you ever attended a meeting with a lymphoma support group?




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.